Definitive Contract 36C25026C0095
- Not listed
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Natera Inc., a biotechnology company specializing in advanced genetic and molecular diagnostic testing services. The contract, valued at $79,200.00, is for genetic testing services, with a period of performance from June 6, 2025, to June 6, 2026. Natera Inc. has been a prime contractor for the VA, providing comprehensive genomic analysis and testing services, including tumor whole...
- Natera Inc. has been awarded a delivery order valued at $73.5K by the Veterans Integrated Service Network 10 (VISN 10), a civilian component of the Department of Veterans Affairs, for next-generation sequencing and peripheral blood circulating tumor DNA (ctDNA) testing services to support VA research initiatives. The contract, awarded on March 3, 2026, with an ultimate completion date of March 2, 2027, operates under a firm fixed-price structure with no set-aside designation, reflecting...
- The U.S. Department of Veterans Affairs (VA) Headquarters awarded a new delivery order worth $499,447.00 to Natera Inc., a global leader in cell-free DNA testing. This order extends the period of performance for six months under an existing indefinite delivery contract between the VA and Natera valued at up to $6.72 million over two years. The contract is for Natera to provide minimal residual disease testing services, which analyze cell-free DNA biomarkers in patient blood samples to detect...
- This $92,391 firm-fixed-price delivery order was awarded by the U.S. Department of Veterans Affairs (VA) to Natera Inc., a leading biotechnology company specializing in advanced genomic and molecular diagnostic testing services. The contract is for minimal residual disease testing services, which support the VA's research and patient care initiatives in oncology and precision medicine. Natera has been awarded multiple federal contracts with the VA, including indefinite delivery contracts...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 6 to Prevention Genetics LLC, a for-profit limited liability company, for genetic testing panels (excluding exome) with a ceiling value of $19,800.00. The contract has an ultimate completion date of September 30, 2024. The original solicitation was for genetic testing services to guide treatment and provide information on gene mutations for patients with prostate...
- The U.S. Department of Veterans Affairs (VA) has awarded a $35,000 firm fixed-price delivery order contract to Natera Inc., a leading biotechnology company, for next-generation sequencing and peripheral blood circulating tumor DNA (ctDNA) testing services in support of cancer research. This contract is not designated as a set-aside. Natera has been a prime contractor for the VA, providing advanced genomic testing and analysis services, including tumor whole exome sequencing, minimal residual...
- The Department of Veterans Affairs, through the Veterans Integrated Service Network 8, awarded a $52.5K purchase order to Ailife Diagnostics, Inc., a woman-owned small business based in Pearland, Texas, for kidney gene panel testing services. The contract, awarded on March 18, 2024, with a completion date of March 19, 2029, supports diagnostic and management capabilities for chronic kidney disease at the Miami VA Medical Center. As specified in the underlying solicitation, Ailife Diagnostics...
- Veterans Integrated Service Network 19 issued a BPA call to Exact Sciences Corporation for Genomic Health genetic testing under the Medical Laboratory Testing and Analysis Services (FSS-621-II) GSA Schedule, with a ceiling value of $73,167.28 and an award date of October 1, 2024. Place of performance is Aurora, Colorado. The ultimate completion date is September 30, 2025. The call is firm fixed price. This is Option Year 4 of an existing BPA framework for specialized genomic and molecular...
- The Department of Veterans Affairs (VA) headquarters awarded an indefinite delivery contract to Natera Inc., doing business as Natera, for up to $6.72 million over two years. This contract covers the delivery of minimal residual disease testing services to detect remaining cancer cells in patients after initial treatment, guiding further treatment decisions. An initial delivery order worth $496,460 was issued to fund research and development activities related to this testing through Fiscal Year...
- The Department of Veterans Affairs, through Veterans Integrated Service Network 8, awarded a delivery order valued at $46,000 to Karius, Inc. for the provision of next-generation sequencing (NGS) testing services. This delivery order, effective through July 31, 2025, represents the third year of testing delivery under a firm fixed-price contract structure with no set-aside designation. Karius, Inc., headquartered in Redwood City, California, is a specialized life sciences company focused on...
Veterans Integrated Service Network 10 awarded a $157,000 definitive contract to Natera Inc. for Natera Kidney Disease Genetic Panel Testing on April 7, 2026, under firm fixed-price terms with no set-aside. Place of performance is Indianapolis, IN. The originating sources-sought notice, posted March 10, 2026, describes laboratory testing services specializing in kidney disease genetic analysis across three specialized service lines: Kidney Gene Panel Testing (analyzing over 380 genes), Kidney Transplant Assessment (non-invasive donor-derived cell-free DNA testing), and Molecular Residual Disease Assay (personalized tumor-informed circulating tumor DNA detection). Testing must be performed domestically by an American Board of Pathology certified pathologist and meet CLIA, CAP, The Joint Commission, HIPAA, and OSHA compliance requirements. Services are provided to three participating VA Medical Centers: Richard L. Roudebush VA Medical Center (Indianapolis, IN), Louis Stokes Cleveland VA Medical Center (Cleveland, OH), and Cincinnati VA Medical Center (Cincinnati, OH). Contract includes specimen collection supplies, paid shipping, secure web-based result reporting, and toll-free customer support. Ultimate completion date is April 6, 2027. NAICS 621511 (Medical Laboratories); PSC Q301 (Medical Reference Laboratory Testing).
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Q301--Kidney Disease Genetic Panel | 36C25026Q0345 | Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 | Pre-Solicitation 1/2 | 3/10/26, 5:09 PM | |
Q301--Kidney Disease Genetic Panel | 36C25026Q0345 | Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 | Special Notice 2/2 | 3/25/26, 1:04 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Supplemental Agreement for work within scope | $0 | 6/25/26 |